Molecular probes for fluorescence image-guided cancer surgery

Ito, Ren; Kamiya, Mako; Urano, Yasuteru

doi:10.1016/j.cbpa.2021.102112

Cited by 25 publications

(17 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Probementioning

confidence: 99%

Molecular imaging of tumour‐associated pathological biomarkers with smart nanoprobe: From “Seeing” to “Measuring”

Zhang,

Li,

Liu

et al. 2023

Exploration

View full text Add to dashboard Cite

Although the extraordinary progress has been made in molecular biology, the prevention of cancer remains arduous. Most solid tumours exhibit both spatial and temporal heterogeneity, which is difficult to be mimicked in vitro. Additionally, the complex biochemical and immune features of tumour microenvironment significantly affect the tumour development. Molecular imaging aims at the exploitation of tumour‐associated molecules as specific targets of customized molecular probe, thereby generating image contrast of tumour markers, and offering opportunities to non‐invasively evaluate the pathological characteristics of tumours in vivo. Particularly, there are no “standard markers” as control in clinical imaging diagnosis of individuals, so the tumour pathological characteristics‐responsive nanoprobe‐based quantitative molecular imaging, which is able to visualize and determine the accurate content values of heterogeneous distribution of pathological molecules in solid tumours, can provide criteria for cancer diagnosis. In this context, a variety of “smart” quantitative molecular imaging nanoprobes have been designed, in order to provide feasible approaches to quantitatively visualize the tumour‐associated pathological molecules in vivo. This review summarizes the recent achievements in the designs of these nanoprobes, and highlights the state‐of‐the‐art technologies in quantitative imaging of tumour‐associated pathological molecules.

show abstract

Section: Probementioning

confidence: 99%

Molecular imaging of tumour‐associated pathological biomarkers with smart nanoprobe: From “Seeing” to “Measuring”

Zhang,

Li,

Liu

et al. 2023

Exploration

View full text Add to dashboard Cite

show abstract

“…In the context of the rise of fluorescence-guided surgery (FGS), the development of bimodal agents combining radioisotope (PET or SPECT) and NIR-emitting optical agents for preclinical and clinical applications is no longer being demonstrated. − The majority of bimodal agents are currently built from a sequential conjugation of, on the one hand, the fluorophore and, on the other hand, the radioisotopic probe (either a radioisotope or a radiometal chelator). This simple approach is currently the most commonly used for the construction of bimodal agents for clinical application . However, it also presents limitations and drawbacks.…”

Section: Introductionmentioning

confidence: 99%

First Comparison Study of the In Vitro and In Vivo Properties of a Randomly and Site-Specifically Conjugated SPECT/NIRF Monomolecular Multimodal Imaging Probe (MOMIP) Based on an aza-BODIPY Fluorophore

et al. 2023

View full text Add to dashboard Cite

Among all approaches in molecular imaging, the combination of near-infrared fluorescence imaging (NIRF) with radioisotopic imaging (PET or SPECT) allows one to benefit from the advantages of each of the imaging techniques, which are very complementary and of comparable sensitivity. To this end, the construction of monomolecular multimodal probes (MOMIP) has made it possible to combine the two imaging modalities within the same molecule, thus limiting the number of bioconjugation sites and yielding more homogeneous conjugates compared with those prepared through sequential conjugation. However, in order to optimize the bioconjugation strategy and, at the same time, the pharmacokinetic and biodistribution properties of the resulting imaging agent, a site-specific approach may be preferred. To further investigate this hypothesis, random and glycan-based site-specific bioconjugation approaches were compared thanks to a SPECT/NIRF bimodal probe based on an aza-BODIPY fluorophore. The overall experiments conducted in vitro and in vivo on HER2-expressing tumors demonstrated a clear superiority of the site-specific approach to improve affinity, specificity, and biodistribution of the bioconjugates.

show abstract

“…Optical molecular imaging is considered to be an important technology for various applications, including tumor diagnosis, staging, monitoring therapeutic response, [9,10] and image-guided surgery. [11] Over the past decade, numerous 1,2-dioxetanebased chemiluminescence probes have been reported for tumor imaging. Thus, this review focuses on 1,2-dioxetanebased probes developed for tumor optical imaging and analyzes the design strategies employed in their development.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

1,2‐Dioxetane‐based Chemiluminescence Probes for Tumor Optical Molecular Imaging

Zhou

Xian

et al. 2023

ChemistrySelect

View full text Add to dashboard Cite

show abstract

Molecular probes for fluorescence image-guided cancer surgery

Cited by 25 publications

References 57 publications

Molecular imaging of tumour‐associated pathological biomarkers with smart nanoprobe: From “Seeing” to “Measuring”

Molecular imaging of tumour‐associated pathological biomarkers with smart nanoprobe: From “Seeing” to “Measuring”

First Comparison Study of the In Vitro and In Vivo Properties of a Randomly and Site-Specifically Conjugated SPECT/NIRF Monomolecular Multimodal Imaging Probe (MOMIP) Based on an aza-BODIPY Fluorophore

1,2‐Dioxetane‐based Chemiluminescence Probes for Tumor Optical Molecular Imaging

Contact Info

Product

Resources

About